clinical trial · NCT05765851
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
Advanced Solid TumorDS-1103aT-DXd
brief summary
This study will evaluate the safety and efficacy of DS-1103a combination therapy in participants with advanced solid tumors.
started
May 30, 2023
primary completion
May 31, 2029
completion
Feb 28, 2031
last updated
Oct 26, 2026
detailed description
DS-1103a, a recombinant humanized IgG4 anti-SIRPα antibody designed to block the SIRPα-CD47 interaction, is being developed for the treatment of advanced cancers in combination with other anticancer therapies. This is the first-in-human, dose-escalation and dose-expansion clinical study designed to assess the safety and efficacy of DS-1103a combination therapy in participants with advanced solid tumors.
official title
A Phase 1, 2-Part, Multicenter, First-In-Human Dose-Escalation and Dose-Expansion Study of DS-1103a Combination Therapy in Subjects With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol